A Delaware federal judge finalized a ruling ordering Guardant Health (NASDAQ:GH) to pay over $245.2 million to TwinStrand Biosciences and the University of Washington, cementing a November 2023 jury verdict that found Guardant willfully infringed on two Duplex Sequencing patents.
Financial Penalty
The penalty covers willful infringement across 11 products and services that generated roughly 90% of Guardant Health’s revenue during the period. The total award includes an initial $83.4 million jury verdict through mid-2023, $19.5 million in post-trial damages through early 2024, $119.4 million from a 6% court-ordered royalty rate through May 2026, and $22.9 million in calculated interest.
Future Royalties And Validity Assured
Moving forward, the court mandates that Guardant Health submit quarterly accounting reports and pay an ongoing 6% royalty on the contested products until the patents officially expire in March 2033.
